^MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) — YPrime

(http://www.yprime.com/), a trusted clinical technology provider

Studies, published today new results showing that the use of

AI achieves measurable quality improvements in the process of eCOA localization –

with 74% fewer migration errors, two-thirds shorter review cycles and

higher global student inclusion.

The one at ISPOR 2025 by Jonathan Norman, Director of Localization & Scale

Management at YPrime, presented study?Garbage In, Garbage Out: Can AI

Reduce the Impact of Human Error in eCOA Localized Text Migration?

(https://www.yprime.com/ai-driven-ecoa-localization-speed-accuracy/)”

examined how AI can address one of the most overlooked aspects of eCOA

Development can improve: migration. This is the process

importing translated Clinical Outcome Assessments (COAs) into digital systems.

YPrime compared a sample of 15 studies in 11 languages

Migration carried out exclusively by humans with the in-house AI

supported migration process. The AI ​​workflow reduced the total number

Migration errors by 74%, reduced the number of incorrect screen reports

by 60% and shortened the localization review process by 67%, with no new ones

Introduce error types.

?Localization is one of the most important – and least automated

– Steps for the global readiness of a study,” said Dr. Karl

McEvoy, Vice President, eCOA and Patient Technologies at YPrime.?This

Research shows that AI when applied to eCOA-specific file structures and

Language rules are trained and can eliminate the most error-prone steps.

This provides linguists and study teams with higher quality

Materials for review. The result is faster, cleaner releases

Data and more inclusive global studies.”

By improving the speed and accuracy of localization

AI enables sponsors to maintain broader language coverage. Through this

Reduces the need to narrow down underrepresented populations

Exclude schedules. Faster release of localized screen reports

enables earlier start of eCOA study builds and first-patient-in-

Milestones, resulting in measurable time and cost benefits for global programs

leads.

The results of this study underscore YPrime’s ongoing commitment

for innovations that deliver measurable efficiency gains in studies. To the

Recent market launches include Advanced eCOA Oversight

(https://www.yprime.com/yprime-advanced-ecoa-oversight/), Automated Data Change

Forms (https://www.yprime.com/yprime-releases-reimagined-ecoa-automated-data-

change-form-for-more-efficient-clinical-trial-data-management/) (DCF) and

Glucometer integrations (https://www.yprime.com/yprime-ecoa-dcf-improves-

clinical trial data management/) for connected device studies. YPrime expanded

continues its AI initiatives within the YPrime eCOA platform, with a focus on

Quality scoring and next-generation localization workflows, automation

balance with human control.

YPrime was recently featured in the?eCOA PEAK Matrix (https://www.yprime.com/yprime-ecoa-

peak-matrix-2025-everest-group/)(®) (https://www.yprime.com/yprime-ecoa-peak-

matrix-2025-everest-group/) Assessment 2025 (https://www.yprime.com/yprime-ecoa-

“peak-matrix-2025-everest-group/)” of the Everest Group was honored as a “Leader”.

This recognizes the company’s proven ability to deliver scalable,

to deliver high quality eCOA solutions that meet the needs of modern clinical

studies in terms of speed and complexity. In addition, that was

Company 2024 as?Trailblazer in Patient Engagement

(https://www.yprime.com/yprime-recognized-as-trailblazer-in-patient-engagement-

by-everest-group/)” and was thus recognized for his commitment,

to develop digital tools that enable access, accuracy and equality in

improve clinical research.

YPrime experts will report these results on Wednesday, December 3, 2025

present in a webinar. For more information, see

www.yprime.events. The full ISPOR poster is on the website

www.yprime.com/resources available.

About YPrime

YPrime simplifies clinical trials with eCOA, IRT and eConsent solutions that

Combine speed, flexibility and quality. The eCOA platform from

YPrime improves patient compliance through an intuitive application and

A user-friendly design streamlines on-site workflows

a powerful eCOA portal that integrates seamlessly into networked devices

and supports sponsors with dashboards for better decisions. The AI

eCOA-powered localization accelerates globalization while

Pre-validated and configurable eCOA and IRT solutions provide faster

Enable study start with quality metrics above industry standards. YPrime

is trusted by both leading pharmaceutical companies and emerging ones

Biotech companies and combines in-depth industry expertise with innovation

to deliver reliable solutions. With almost two decades of evidence

Successes, solutions in over 250 languages ​​and support in more than 100 countries

YPrime is your partner for reliably managing clinical problems

Research challenges. Visit www.yprime.com or send an email

Email [email protected] (mailto:[email protected]).

Media contact

Grace Mohren

Senior Vice President, Marketing, YPrime

[email protected]

You can find a photo of this announcement

at: https://www.globenewswire.com/NewsRoom/AttachmentNg/c3d3b4f4-d80f-

4cc1-8051-78e3de911804

°

ttn-28